Subgroup analyses of elderly patients aged ≥ 70 years in MAGNIFY: A phase 3b interim analysis of induction R2 followed by maintenance in Relapsed/Refractory indolent non-Hodgkin lymphoma

被引：0

作者：

Rummel, M. J. ^{[1
]}

Lansigan, F. ^{[2
]}

Andorsky, D. J. ^{[3
]}

Coleman, M. ^{[4
]}

Yacoub, A. ^{[5
]}

Melear, J. M. ^{[6
]}

Fanning, S. R. ^{[7
]}

Kolibaba, K. S. ^{[8
]}

Reynolds, C. ^{[9
]}

Nowakowski, G. ^{[10
]}

Gharibo, M. ^{[11
]}

Ahn, E. ^{[11
]}

Li, J. ^{[11
]}

Sharman, J. P. ^{[12
]}

机构：

[1] Justus Liebig Univ, Giessen, Germany

[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[3] US Oncol Res, Rocky Mt Canc Ctr, Boulder, CO USA

[4] Weill Cornell Med, Clin Res Alliance Inc, New York, NY USA

[5] Univ Kansas Canc Ctr, Westwood, KS USA

[6] US Oncol Res, Texas Oncol Austin, Austin, TX USA

[7] US Oncol Res, Prisma Hlth, Greenville, SC USA

[8] US Oncol Res, Vancouver, WA USA

[9] IHA Hematol Oncol Consultants Ann Arbor, Ypsilanti, MI USA

[10] Mayo Clin, Rochester, MN USA

[11] Bristol Myers Squibb, Princeton, NJ USA

[12] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ep487

引用

页码：154 / 154

页数：1

共 50 条

[1] Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Lansigan, Frederick
Andorsky, David Jacob
Coleman, Morton
Yacoub, Abdulraheem
Melear, Jason M.
Fanning, Suzanne R.
Kolibaba, Kathryn S.
Reynolds, Christopher M.
Nowakowski, Grzegorz S.
Gharibo, Mecide
Ahn, Erin
Li, Ju
Rummel, Mathias J.
Sharman, Jeff P.
BLOOD, 2020, 136
[2] MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.
Andorsky, David Jacob
Coleman, Morton
Yacoub, Abdulraheem
Melear, Jason M.
Fanning, Suzanne R.
Kolibaba, Kathryn
Lansigan, Frederick
Reynolds, Chris
Foon, Kenneth A.
Li, Jiahui
Llorente, Mary
Rummel, Mathias J.
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Lansigan, Frederick
Andorsky, David Jacob
Coleman, Morton
Yacoub, Abdulraheem
Melear, Jason M.
Fanning, Suzanne R.
Kolibaba, Kathryn S.
Reynolds, Chris
Nowakowski, Grzegorz S.
Gharibo, Mecide
Ahn, Jung Ryun
Li, Ju
Rummel, Mathias J.
Sharman, Jeff P.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 104 - 105
[4] MAGNIFY Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed by Maintenance in Relapsed/ Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis
Lansigan, Frederick
Andorsky, David Jacob
Coleman, Morton
Yacoub, Abdulraheem
Melear, Jason M.
Fanning, Suzanne R.
Kolibaba, Kathryn S.
Reynolds, Chris
Nowakowski, Grzegorz S.
Gharibo, Mecide
Ahn, Jung Ryun
Li, Ju
Rummel, Mathias J.
Sharman, Jeff P.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S384 - S384
[5] Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide plus Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin
Frederick, Lansigan
David, J. Andorsky
Morton, Coleman
Yacoub, Abdulraheem
Jason, M. Melear
Suzanne, R. Fanning
Kathryn, S. Kolibaba
Chris, Reynolds
Grzegorz, S. Nowakowski
Mecide, Gharibo
Jung, R. Ahn
Ju, Li
Mathias, D. Rummel
Jeff, P. Sharman
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S9 - S10
[6] Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide plus Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Lansigan, Frederick
Andorsky, David Jacob
Coleman, Morton
Yacoub, Abdulraheem
Melear, Jason
Fanning, Suzanne
Kolibaba, Kathryn S.
Reynolds, Christopher M.
Nowakowski, Grzegorz S.
Gharibo, Mecide
Ahn, Jung Ryun
Li, Ju
Rummel, Mathias J.
Sharman, Jeff P.
BLOOD, 2021, 138
[7] MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL.
Andorsky, David Jacob
Coleman, Morton
Yacoub, Abdulraheem
Melear, Jason M.
Fanning, Suzanne R.
Kolibaba, Kathryn
Lansigan, Frederick
Reynolds, Chris
Foon, Kenneth A.
Li, Jiahui
Llorente, Mary
Rummel, Mathias J.
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance
Coleman, Morton
Andorsky, David Jacob
Yacoub, Abdulraheem
Melear, Jason M.
Fanning, Suzanne R.
Kolibaba, Kathryn S.
Lansigan, Frederick
Reynolds, Christopher M.
Nowakowski, Grzegorz S.
Gharibo, Mecide
Ahn, Erin
Li, Ju
Rummel, Mathias J.
Sharman, Jeff P.
BLOOD, 2020, 136
[9] MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction followed by rituximab (R) maintenance.
Andorsky, David Jacob
Franson, Paula J.
Mouro, Jorge L.
Li, Jiahui
Foon, Kenneth A.
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL)
Andorsky, David J.
Cataruozolo, Patricia E.
Mouro, Jorge L.
Li, Ju
Fustier, Pierre
Foon, Kenneth A.
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →